{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:28:44Z","timestamp":1793651324685,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.hoc.2026.08.007","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:34:07Z","timestamp":1790595247000},"page":"955-966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tissue-Based Trials"],"prefix":"10.1016","volume":"40","author":[{"given":"Charuta G.","family":"Furey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Chi","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artak","family":"Tovmasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwetal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Sanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2026.08.007_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J Health Econ"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.007_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.007_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","article-title":"Glioblastoma clinical trials: current landscape and opportunities for improvement","volume":"28","author":"Bagley","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.007_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(25)00705-3","article-title":"20 years of the stupp protocol: confronting stagnation in glioblastoma therapy","volume":"27","author":"Khasraw","year":"2026","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.007_bib5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1093\/neuonc\/noad036","article-title":"A critical analysis of neuro-oncology clinical trials","volume":"25","author":"Kim","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.007_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219724","article-title":"Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas","volume":"14","author":"Berens","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.007_bib8","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1016\/S1470-2045(24)00190-6","article-title":"A brave new framework for glioma drug development","volume":"25","author":"Hotchkiss","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.007_bib9","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/s41591-023-02464-8","article-title":"Correcting the drug development paradigm for glioblastoma requires serial tissue sampling","volume":"29","author":"Singh","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.007_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","article-title":"Phase 0\/microdosing approaches: time for mainstream application in drug development?","volume":"19","author":"Burt","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2026.08.007_bib11","series-title":"Guidance for industry, investigators, and reviewers: exploratory IND studies","year":"2006"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.007_bib12","doi-asserted-by":"crossref","first-page":"E967","DOI":"10.1093\/neuros\/nyz218","article-title":"Phase 0 clinical trial strategies for the neurosurgical oncologist","volume":"85","author":"Sanai","year":"2019","journal-title":"Neurosurgery"},{"issue":"16","key":"10.1016\/j.hoc.2026.08.007_bib13","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","article-title":"Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients","volume":"24","author":"Sanai","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10412","key":"10.1016\/j.hoc.2026.08.007_bib14","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","article-title":"Primary brain tumours in adults","volume":"402","author":"van den Bent","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdac087","article-title":"The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review","volume":"4","author":"Swildens","year":"2022","journal-title":"Neuro-oncology advances"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.007_bib16","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdab053","article-title":"Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study","volume":"3","author":"M\u00fcller","year":"2021","journal-title":"Neuro-oncology advances"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3171\/2023.5.JNS23388","article-title":"Does waiting for surgery matter? How time from diagnostic MRI to resection affects outcomes in newly diagnosed glioblastoma","volume":"140","author":"Young","year":"2024","journal-title":"J Neurosurg"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.007_bib19","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1021\/acs.jmedchem.5c00725","article-title":"Free drug concepts: a lingering problem in drug discovery","volume":"68","author":"Webborn","year":"2025","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.007_bib20","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/neuonc\/noag051","article-title":"Evaluating \"brain permeability\": a critical issue for the development of therapeutic agents for primary and metastatic brain tumors","volume":"28","author":"Grossman","year":"2026","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.007_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noae005","article-title":"Leveraging external control data in the design and analysis of neuro-oncology trials: pearls and perils","volume":"26","author":"Polley","year":"2024","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.007_bib22","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41591-025-03884-4","article-title":"Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial","volume":"31","author":"Drummond","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.007_bib23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib24","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11060-008-9678-2","article-title":"Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study","volume":"91","author":"Blakeley","year":"2009","journal-title":"J Neuro-oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.007_bib26","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S1470-2045(23)00453-9","article-title":"A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups","volume":"24","author":"Karschnia","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.007_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","article-title":"Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective","volume":"187","author":"Mathur","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2026.08.007_bib28","series-title":"NCI best practices for biospecimen resources","year":"2016"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.007_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/cncy.20147","article-title":"Biospecimen reporting for improved study quality (BRISQ)","volume":"119","author":"Moore","year":"2011","journal-title":"Cancer cytopathology"},{"issue":"16","key":"10.1016\/j.hoc.2026.08.007_bib30","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","article-title":"Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies","volume":"27","author":"Kummar","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2026.08.007_bib31","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.007_bib32","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/neuonc\/nou103","article-title":"A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report","volume":"16","author":"Su","year":"2014","journal-title":"Neuro Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.08.007_bib33","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","article-title":"A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor Pharmacodynamic- and pharmacokinetic-guided expansion cohort","volume":"25","author":"Tien","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.007_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.007_bib35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.007_bib36","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/noaa061","article-title":"Way to Go\/No-Go","volume":"22","author":"Lesser","year":"2020","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.007_bib37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-Kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial","volume":"37","author":"Wen","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:56:11Z","timestamp":1793649371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0889858826001085"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue-Based Trials","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}